Nakagawa T et al. (Nakagawa et al., 2014) found that combination of LVN and golvatinib could dramatically decrease the hepatocyte growth factor (HGF)-induced resistance via decreasing tumor vessel density in four HCC xenograft models (Gherardi et al., 2012). This evidence concerns the gene HGF and neoplasm.